Sumithra J Mandrekar, PhD

Professor, Rochester, MN, Health Sciences Research

EmailMandrekar.Sumithra@mayo.edu

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Sumithra J Mandrekar is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

16 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

1 Finished
3 Not started

Mayo Clinic Hepatobiliary SPORE
Mandrekar, S. J., Torbenson, M., Gores, G. J., Alberts, S. R. & Vile, R. G.
Project: Research project
Validation of New Tumor Measurement-based Phase II Clinical Trial Endpoints
Mandrekar, S. J., Kinney, L., Kinney, L., Kinney, L. & Kinney, L.
Project: Research project
Statistics and Data Center for the Alliance for Clinical Trials in Oncology
Mandrekar, S. J.
Project: Research project
Methodology for development, validation, and use of novel endpoints in oncology
Mandrekar, S. J. & Kinney, L.
2/1/14 → 1/31/18
Project: Research project

7008 Citations
41 Scopus h-Index
125 Article
17 Review article
5 Editorial
4 Comment/debate
5 More

Adverse event burden score—a versatile summary measure for cancer clinical trials
Le-Rademacher, J., Hillman, S., Storrick, E., Mahoney, M. R., Thall, P. F., Jatoi, A. & Mandrekar, S. J., Nov 2020, In : Cancers. 12, 11, p. 1-15 15 p., 3251.
Research output: Contribution to journal › Article › peer-review

Open Access
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance)
Parikh, K., Mandrekar, S. J., Allen-Ziegler, K., Esplin, B., Tan, A. D., Marchello, B., Adjei, A. A. & Molina, J. R., Jun 1 2020, In : Oncologist. 25, 6, p. 523-531 9 p.
Research output: Contribution to journal › Article › peer-review
A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study
Schenk, E. L., Mandrekar, S. J., Dy, G. K., Aubry, M. C., Tan, A. D., Dakhil, S. R., Sachs, B. A., Nieva, J. J., Bertino, E., Lee Hann, C., Schild, S. E., Wadsworth, T. W., Adjei, A. A. & Molina, J. R., Jan 2020, In : Journal of Thoracic Oncology. 15, 1, p. 110-119 10 p.
Research output: Contribution to journal › Article › peer-review
5 Scopus citations
Clinical Versus Statistical Significance in Studies of Thoracic Malignancies
Dahlberg, S. E., Korn, E. L., Le-Rademacher, J. & Mandrekar, S. J., Sep 2020, In : Journal of Thoracic Oncology. 15, 9, p. 1406-1408 3 p.
Research output: Contribution to journal › Article › peer-review

1 Scopus citations
Guidelines for Statistical Reporting in Medical Journals
Ou, F. S., Le-Rademacher, J. G., Ballman, K. V., Adjei, A. A. & Mandrekar, S. J., Nov 2020, In : Journal of Thoracic Oncology. 15, 11, p. 1722-1726 5 p.
Research output: Contribution to journal › Review article › peer-review